HighMark Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

HighMark Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Hold	23,000	–	–	0.47%	33
2026 Q1	$1.34M	Hold	23,000	–	–	0.54%	26
2025 Q4	$1.03M	Sell	23,000 -3,100	-12%	-$130K	0.42%	33
2025 Q3	$1.05M	Hold	26,100	–	–	0.46%	30
2025 Q2	$817K	Buy	26,100 +20,000	+328%	+$652K	0.4%	34
2025 Q1	$205K	Hold	6,100	–	–	0.12%	55
2024 Q4	$239K	Buy	6,100 +1,100	+22%	+$45.5K	0.14%	47
2024 Q3	$197K	Hold	5,000	–	–	0.11%	65
2024 Q2	$195K	Hold	5,000	–	–	0.12%	64
2024 Q1	$215K	Buy	+5,000	New	+$230K	0.13%	57

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HighMark Wealth Management's XENE Position: Q2 2026 in Review

HighMark Wealth Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 23,000 shares worth $1.39M. The position accounts for 0.47% of the portfolio, ranked #33.

HighMark Wealth Management first reported a position in XENE in Q1 2024 and has held it in 10 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

HighMark Wealth Management held 23,000 shares of Xenon Pharmaceuticals worth $1.39M as of Q2 2026.
HighMark Wealth Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 0.47% of HighMark Wealth Management's portfolio in Q2 2026, its #33 holding.
HighMark Wealth Management first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.